Mikael Anttinen

About

Dr. Mikael Anttinen is a leading researcher in the field of prostate cancer diagnostics and focal therapy. His work centers on advancing precision medicine for prostate cancer, with key contributions in MRI-guided transurethral ultrasound ablation (TULSA) and novel PET/CT imaging techniques. Dr. Anttinen’s seminal 2019 study on TULSA (30 citations) established the feasibility and safety of this minimally invasive approach for lesion-targeted ablation, demonstrating high accuracy and favorable short-term outcomes for organ-confined disease. He further characterized the post-treatment imaging landscape in a 2020 study (8 citations), providing critical benchmarks for evaluating treatment response on MRI. More recently, his 2025 prospective comparison of 18F-PSMA-1007 PET/CT versus MRI (6 citations) has significantly advanced the detection and T-staging of high-risk prostate cancer, directly correlating PSMA uptake with histopathological expression. With over 44 cumulative citations, Dr. Anttinen’s work bridges cutting-edge imaging and targeted therapy, offering patients less invasive, more precise treatment options while setting new standards for post-treatment surveillance.

Research Focus

Key Achievements

Top Papers

1. 1
   Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

   30 citations · 2019
2. 2
   Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer

   8 citations · 2020
3. 3
   Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer

   6 citations · 2025

Key Collaborators

Contact & Links